RO7694744 / Roche - LARVOL DELTA

Advancing cancer immunotherapy: PD-L1-targeted IFNa2a fusion protein RO7694744 (AACR 2025) - "The explant data supported our previous findings, demonstrating PD-L1 specificity and dependency of RO7694744.Our preclinical findings illustrate that RO7694744 selectively targets and activates PD-L1 expressing tumor and immune cells. Clinical experience is needed to confirm whether this targeted strategy can enhance therapeutic efficacy while minimizing adverse effects, thus addressing the key challenge of untargeted IFNa in cancer immunotherapy."

IO biomarker • Oncology • IFNAR1

Advancing cancer immunotherapy: Unveiling the potential of PD-L1-targeted IFN-α2a dutaflip molecule through patient-derived tumor explants (AACR 2025) - "These findings enhance the understanding of RO7694744's MOA, confirming its PD-L1-dependent tumor targeting and activity within the TME. This supports a patient selection strategy and identifies clinically-relevant pharmacodynamic biomarkers."

Clinical • IO biomarker • Bladder Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • IFNA1 • IFNG • PD-L1